New

Inherited Disease

Seraseq® Inherited Cancer DNA Mix v2

Material Number 0730-0069
Size 1 x 25µL
Inventory Status In Stock
Unit EA

The Seraseq Inherited Cancer DNA Mix v2 is a reference material intended for use in the development, validation, and evaluation of routine performance of Next Generation Sequencing (NGS) (and other amplified nucleic acid-based methods) that identify inherited (germline) variants in genes associated with hereditary cancer such as BRCA1, BRCA2, MHS2 and many others. 

This high-quality reference material is a mixture of synthetic DNA constructs and genomic DNA extracted from the human cell line GM24385, formulated to simulate a heterozygous state for each mutation at a 50% variant allele frequency. It contains an unprecedented 61 synthetic mutations in 55 cancer-predisposing genes allowing laboratories to address assay challenges with a diverse array of mutations, including complex and hard-to-find variants such as the MSH2 Boland inversion, PMS2 pseudogene homologous variant, and EPCAM 3' large deletion (see technical spreadsheet for detailed information).  

FEATURES AND BENEFITS 

  • Comprehensive Variant Coverage: Screen confidently for 61 clinically relevant variants across 56 cancer-associated genes. This enhanced coverage offers 2.5 times more mutations than our previous version, ensuring even rare and challenging variants are accounted for. 
  • Unmatched Complexity: incorporates difficult-to-detect mutations, such as the MSH2 Boland inversion, PMS2 pseudogene homologous variant, and EPCAM 3' large deletion, ensuring robust testing capabilities. 
  • High Variant Diversity: includes deletions, duplications, insertions, INDELs, SNVs, and inversions as well as a variety of complex variant types such as homopolymer variants, high-GC region variants, microsatellite variants, whole exon deletion, and deep splice site variants. 
  • Single-Vial Convenience: Simplify workflows with a highly multiplexed reference material packaged in a single vial, reducing costs and saving time while boosting QC consistency. 
  • Regulatory Compliance Support: designed to support compliance with regulatory standards like CAP, CLIA ensures your lab meets performance, quality, and reporting requirements effortlessly. 
  • Sustainable source: Manufactured in GMP-compliant, ISO 13485-certified facilities, the Seraseq Inherited Cancer DNA Mix v2 offers lot-to-lot consistency and an uninterrupted supply chain. 

Package Insert for Seraseq Inherited Cancer DNA Mix v2

Doc type
Package Insert

Safety Data Sheet for Seraseq Inherited Cancer DNA Mix v2

Doc type
Safety Data Sheet

Technical Spreadsheet for Seraseq Inherited Cancer DNA Mix v2

Doc type
Technical Spreadsheet

Seraseq Inherited Cancer DNA Mix v2

Doc type
Certificate of Analysis
Lot #
10711165

Product Sheet for Seraseq Inherited Cancer DNA Mix v2

Doc type
Product Sheet

Product Specifications  

Number of genes 

61 

Number of variants 

55 

Variant allele Frequency % (VAF) 

50 

Number of vial 

1 

Fill Volume 

25 µL (actual fill volume: 30 µL) 

Concentration 

10 ng/µL 

Total Mass 

>250 ng 

Matrix 

Purified DNA in Buffer (Tris/EDTA)